Table 1.

Response Rates in Clinical Trials of Ixabepilone Monotherapy in Metastatic Breast Cancer: Key Phase 2 Trials

Trial	Eligibility Criteria	No.	Dose and Schedule	Response Rate
Baselga et al.41	Neoadjuvant therapy in patients with locally advanced breast cancer	164	40 mg/m2 q3w	pCR rate, 19%
Denduluri et al.40	1st- or >2nd-line therapy in patients with taxanenaive MBC	23	6 mg/m2 days 1–5 q3w	ORR, 57%; SD rate, 26%
Roché et al.39	1st-line therapy in patients with MBC previously treated with an adjuvant anthracycline	65	40 mg/m2 q3w	ORR, 41.5%; SD rate, 35%
Low et al.38	1st- 2nd-, or >3rd-line therapy in patients previously treated with a taxane as prior neoadjuvant, adjuvant, or metastatic therapy	37	6 mg/m2 days 1–5 q3w	ORR, 22%; SD rate, 35%
Thomas et al.37	1st-, 2nd-, 3rd-, or 4th-line therapy in patients with taxane-resistant MBC	49	40 mg/m2 q3w	ORR, 12%; SD rate, 41%
Perez et al.36	3rd- or 4th-line therapy in patients with MBC resistant to anthracyclines, taxanes, and capecitabine	126	40 mg/m2 q3w	ORR, 11.5%; SD rate, 50%
Denduluri et al.42	Patients with MBC who have received prior taxane therapy	12	8–10 mg/m2 q3w	ORR, 0%; SD rate for ≥6 weeks, 83%

MBC = metastatic breast cancer; ORR = objective response rate; q3w = every 3 weeks; pCR = pathological complete response; SD = stable disease.